|
1)
Avandia lowers something other than blood sugar…
The drug appears to
lower the "good" cholesterol (HDL). This is not a happy finding
because the HDL molecules act like "boxcars" to carry away the
"bad" cholesterol. The "double whammy" is that patients with
diabetes should be on lipid lowering therapy.
http://story.news.yahoo.com/news?tmpl=story&cid=594&ncid=594&e=12&u=/nm/20041126/hl_nm/avandia_lipid_dc
2) Stop the bloody
antidepressants?
Not exactly new news
but another paper suggesting that your chances of a bleed double
with use of certain antidepressants. It should be noted that
your chances of recurring depression more than double if you
stop the antidepressant. It is, once again, a
risk-versus-benefit choice.
http://www.medscape.com/viewarticle/494691?src=mp
3) "Triple whammy?"
… and people with
diabetes are more likely to develop depression!
Type 1 (insulin
dependent or juvenile ) diabetes is more genetic. You can avoid
acquiring type II diabetes (adult onset) by watching you weight…
you may be a "diabetic waiting to happen". Hope this doesn't
depress you.
http://www.foxnews.com/story/0,2933,139561,00.html
4) Bextra gets a black
box.
Bextra, one of the two
remaining COX II inhinitors with the demise of Vioxx, just
received a change in the official labeling. A BLACK BOX waring
is meant to alert prescribers to extra-ordinary dangers that
must be considered before writing for the drug. In this case,
physicians are alerted to a higher incidence of
Stevens-Johnson's Syndrome in Bextra users. This is a rare,
idiosyncratic reaction (like an allergy) that may occur within
the first 2 weeks of therapy (or later in a few cases). It is
serious problem if it occurs. Physicians have been sent 2
letters by the manufacturer warning about this potential side
effect so there is nothing more to do at this time. It will get
more press that it would have deserved except for the recent
Vioxx press.
http://www.pfizer.com/download/uspi_bextra.pdf |